Infection prevention & Control Market by Infections 2023 | IndustryARC
  • 1-614-588-8538 (Ext: 101)
  • US Toll Free

Infection prevention & control market
Infection prevention & Control Market: By Infections (Microbial & Others); By Antimicrobial Drugs (Antibacterial & Others); By Accessories & Equipment (Disinfectants & Others); By End User (Equipment & Drug Usage) & By Geography - (2018-2023)
Report Code : HCR 0022
Updated Date: 15 May, 2018  
10

Copies sold

    Client Rating

  • Report Description
  • Table of Contents
  • Tables And Figures
  • Customization Options
1.Market Overview
2.Executive Summary
3.Infection prevention & control system Market Landscape
   3.1.Market Share Analysis
   3.2.Comparative Analysis
      3.2.1.Product Benchmarking
      3.2.2.End User profiling
      3.2.3.Patent Analysis
      3.2.4.Top 5 Financials Analysis
4.Infection prevention & control system Market Forces
   4.1.Market Drivers
   4.2.Market Constraints
   4.3.Market Challenges
   4.4.Attractiveness of the Industry
      4.4.1.Power of Suppliers
      4.4.2.Power of Customers
      4.4.3.Threat of New entrants
      4.4.4.Threat of Substitution
      4.4.5.Degree of Competition
5.Infection prevention & control system Market – Strategic Analysis
   5.1.Value Chain Analysis
   5.2.Pricing Analysis
   5.3.Opportunities Analysis
   5.4.Product/Market Life Cycle Analysis
   5.5.Suppliers and Distributors
6.Infection prevention & control system Market- By Infections
   6.1.Microbial infections
      6.1.1.Bacterial infection
            6.1.1.1.Mycobacterium tuberculosis
            6.1.1.2.Clostridium Difficile
            6.1.1.3.E. Coil
            6.1.1.4.Helicobacter pylori
            6.1.1.5.Salmonella
            6.1.1.6.Others
      6.1.2.Viral infection
            6.1.2.1.Ebola Virus
            6.1.2.2.Human Immunodeficiency Virus (HIV)
            6.1.2.3.Herpes Simplex Virus
            6.1.2.4.Yellow Fever
            6.1.2.5.Dengue Viruses
            6.1.2.6.Junin Virus
            6.1.2.7.KFD (Kyasanur Forest Virus)
            6.1.2.8.Machupo Virus
            6.1.2.9.Others
      6.1.3.Fungal Infection 
            6.1.3.1.Cryptococcus Gatti
            6.1.3.2.Aspergillis
            6.1.3.3.Pneumocystis Pneumonia
            6.1.3.4.Gungal Keratitis
            6.1.3.5.Dermatophytes
            6.1.3.6.Exserohilum 
            6.1.3.7.Cladosporium
            6.1.3.8.Other
   6.2.Healthcare Associated Infections
      6.2.1.Hospital Acquired Infection
            6.2.1.1.Central line associated bloodstream infection (CLABSI)
            6.2.1.2.Catheter associated Urinary Tract infection
            6.2.1.3.Surgical site infection 
            6.2.1.4.Ventilator associated Pneumonia (VAP) infection
      6.2.2.Community acquired infection 
            6.2.2.1.Methicillin resistant Staphylococcus aureus (MRSA) infection
            6.2.2.2.Community acquired pneumonia 
7.Infection prevention & control system Market- By Antimicrobial drugs
   7.1.Anti-bacterial Drug
   7.2.Anti-Viral Drug
   7.3.Anti-fungal Drug
   7.4.Vaccine
8.Infection prevention & control system Market- By Accessories and Equipment
   8.1.Personal Protective Equipment
      8.1.1.Gloves
      8.1.2.Surgical Masks & Respirators
      8.1.3.Surgical Drapes & Gown
      8.1.4.Surgical Foot covers 
      8.1.5.Medical safety Glasses
      8.1.6.Others
   8.2.Disinfectants
      8.2.1.Hand sanitizers
      8.2.2.Disinfectants wipes
      8.2.3.Surface Disinfectants
      8.2.4.Instrument Disinfectants
      8.2.5.Environmental Disinfectants
      8.2.6.Others
   8.3.Sterilization
      8.3.1.Medical Device Sterilization Equipment
            8.3.1.1.Wet/Stream Sterilization (Autoclave)
                     8.3.1.1.1.Vertical Autoclave
                     8.3.1.1.2.Horizontal Autoclave
                     8.3.1.1.3.Portable Autoclave
            8.3.1.2.Dry Heat Sterilization
            8.3.1.3.Low Temperature Sterilization
                     8.3.1.3.1.In-House Steam Sterilization
                     8.3.1.3.2.Ethylene Oxide (EO) Sterilization
                     8.3.1.3.3.Gamma and eBeam Sterilization
9.Infection prevention & control system Market- By End User Industry
   9.1.End Users: By Equipment Usage
      9.1.1.Hospitals & Clinics
      9.1.2.Medical Laboratories
      9.1.3.Manufacturing Units
            9.1.3.1.Pharmaceuticals
            9.1.3.2.Medical Devices
            9.1.3.3.Food & Beverages 
   9.2.End users: By Drug Usage
      9.2.1.Individuals & Patients
      9.2.2.Nursing & Senior care Centers 
10.Infection prevention & control system Market - By Geography
   10.1.North America 
      10.1.1.U.S.  
      10.1.2.Canada 
      10.1.3.Mexico 
      10.1.4.Rest of North America
   10.2.South America 
      10.2.1.Brazil 
      10.2.2.Venezuela
      10.2.3.Argentina
      10.2.4.Ecuador
      10.2.5.Peru
      10.2.6.Colombia 
      10.2.7.Costa Rica
      10.2.8.Rest of South America
   10.3.Europe 
      10.3.1.U.K 
      10.3.2.Germany 
      10.3.3.Italy 
      10.3.4.France
      10.3.5.Netherlands
      10.3.6.Belgium
      10.3.7.Spain
      10.3.8.Denmark
      10.3.9.Rest of Europe
   10.4.APAC
      10.4.1.China 
      10.4.2.Australia 
      10.4.3.South Korea
      10.4.4.India
      10.4.5.Taiwan
      10.4.6.Malaysia
      10.4.7.Hong Kong  
      10.4.8.Rest of APAC
   10.5.Middle East& Africa 
      10.5.1.Israel
      10.5.2.South Africa
      10.5.3.Saudi Arabia
   10.6.Rest of Middle East and Africa
11.Market Entropy
   11.1.New Product Launches
   11.2.M&As, Collaborations, JVs, Partnership
12.Company Profiles (Overview, Financials, SWOT Analysis, Developments, Product Portfolio)
   12.1. ABBOTT LABORATORIES (ABBOTT DIACNOSTICS)
   12.2.ALERE
   12.3.ANSELL LIMITED
   12.4.ASTRAZENECEA
   12.5.BARD (CR) INCORPORATED
   12.6.BECTON, DICKINSON AND COMPANY
   12.7.BELIMED
   12.8.CANTEL
   12.9.COVIDIEN PLC
   12.10.GETINGE GROUP
   12.11.Company 11
   12.12.Company 12
   12.13.Company 13
   12.14.Company 14
   12.15.Company 15+
*More than 10 Companies are profiled in this Research Report*
"*Financials would be provided on a best efforts basis for private companies"
13.Appendix
   13.1.Abbreviations
   13.2.Sources
   13.3.Research Methodology
   13.4.Bibliography
   13.5.Compilation of Expert Insights
   13.6.Disclaimer
Global infection prevention and control market by infection is valued at $141.9 billion in the year 2017 and is expected to grow with a CAGR of 6.1% from 2018 to 2023. The global infection prevention and control system is segmented based on different types of equipment’s in which gloves holds the major market share followed by surgical masks and respirators. Gloves valued at $29.2 billion followed by surgical masks and respirators i.e. $19.3 billion in the year 2017 and is anticipated to grow with a CAGR of 6.1% and 5.3% respectively during the forecast period i.e. 2018 to 2022. Growing awareness towards prevention and control of cross infection in hospitals and clinics will drive the growth of gloves market.

What is Infection Prevention and Control Market?
Infection prevention and control is to prevent the transmission of communicable disease. For the prevention of any infection one should have the basic understanding of the infection and the risk of the infection. Infection prevention and control system includes the necessary products to prevent the cross infection from equipment, surface and skin of patient and healthcare staff. Infection prevention and control market is segmented based on the different types of infections, types of anti-microbial drugs. There are different types of anti-microbial drugs like anti-bacterial drug, anti-viral drug and anti-fungal drug.



Market Research and Market Trends of Infection prevention and control Market:
  • A harmless bacteria called Lactobacillus is used for treating generic issues such as digestion problems and skin disorders. This bacteria can also be found in dietary supplements, yogurts and some other fermented foods. Companies in various countries are trying to employ this bacteria to address diseases such as periodontal and caries. The innovation intensity in this particular space is quite high and recently mouth rinses and probiotic toothpastes enabled with lactobacillus bacteria has been introduced in the Chinese market. This further suggest the increase in use of lactobacillus bacteria in various consumable products.
  • Approximately 5% of the patients going through surgical procedure develops healthcare associated infection such as urinary tract infection, postoperative respiratory and others from the surgical sites. Thus the market is moving towards the infection prevention before surgical procedure. Companies are heavily investing in the antimicrobial cleansers to rinse the patient body and any infections before any surgical procedure. This process is expected to widely use in both developed and developing countries.
  • A bacteria called Clostridium difficile is the major source of infections in hospitals. UV light can act as an antimicrobial technology to destroy the DNA inside the bacteria, fungi and viruses. For sanitizing drinking water and disinfect industrial surfaces UV light has been used for decades. Hospitals are also gaining traction for UV light from quite some time. To address the need, companies are coming up with the innovative solution to maintain the hygienic environment. Recently a company called UVC Cleaning Systems introduced a stationary UV device which keeps the patient away from all infections which is designed to be mounted on the hospital and other institution walls.

Who are the Major Players in Infection prevention and control market?
The companies referred in the market research report includes Abbott laboratories (Abbott diacnostics), Alere, Ansell limited, Astrazenecea, Bard (cr) incorporated, Becton, dickinson and company, Belimed more than 10 other companies.

What is our report scope?
The report incorporates in-depth assessment of the competitive landscape, product market sizing, product benchmarking, market trends, product developments, financial analysis, strategic analysis and so on to gauge the impact forces and potential opportunities of the market. Apart from this the report also includes a study of major developments in the market such as product launches, agreements, acquisitions, collaborations, mergers and so on to comprehend the prevailing market dynamics at present and its impact during the forecast period 2018-2023.

All our reports are customizable to your company needs to a certain extent, we do provide 20 free consulting hours along with purchase of each report, and this will allow you to request any additional data to customize the report to your needs.

Key Takeaways from this Report
  • Evaluate market potential through analyzing growth rates (CAGR %), Volume (Units) and Value ($M) data given at country level – for product types, end use applications and by different industry verticals.
  • Understand the different dynamics influencing the market – key driving factors, challenges and hidden opportunities.
  • Get in-depth insights on your competitor performance – market shares, strategies, financial benchmarking, product benchmarking, SWOT and more.
  • Analyze the sales and distribution channels across key geographies to improve top-line revenues.
  • Understand the industry supply chain with a deep-dive on the value augmentation at each step, in order to optimize value and bring efficiencies in your processes. 
  • Get a quick outlook on the market entropy – M&A’s, deals, partnerships, product launches of all key players for the past 4 years. 
  • Evaluate the supply-demand gaps, import-export statistics and regulatory landscape for more than top 20 countries globally for the market. 
List of Tables:

Table 1. Global IP&C Market Key Players, Market Shares By Revenue 2013 (%)
Table 2. Product Benchmarking for Surgical N95 Mask – By Pricing
Table 3. Product Benchmarking for Anti-Bacterial Drugs: By Key Players
Table 4. Key Patents By IP&C Player In 2014
Table 5. Top Five Financial Analysis for IP&C Market 2013 ($Million)
Table 6. Cost of Surgical Procedures (In $): By Disease Indication
Table 7. Population above 65 Years of Age, By Region (Millions)
Table 8. Top Company’s Patent Cliff Analysis (Patent Expiry 2014)
Table 9. List of Drug-Resistant Infectious Agents; By Country/ Region (%)
Table 10. U.S. Statistics of Drug Resistant Tuberculosis In 2013
Table 11. List of Few Common Human Viruses Associated With Cancer
Table 12. Global IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 13. North America IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 14. Europe IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 15. IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 16. Row IP&C Anti Microbial Drugs Market, By Microbial Infections, 2013-2020 ($Billion)
Table 17. Economics Cost Associated With Hospital-Acquired Infection
Table 18. Rate of the Infection WRT Device-Associated Infections
Table 19. Global IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 20. North America IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 21. Europe IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 22. APAC IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 23. Row IP&C Accessories & Equipment Market, By Hai, 2013-2020 ($Billion)
Table 24. List of Recently Approved Anti- Bacterial Drugs (2000-2014)
Table 25. List of Approved Antiviral Drugs
Table 26. List of Approved Anti- Fungal Drugs
Table 27. List of Approved Preventive Vaccines
Table 28. Global IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 29. North America IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 30. Europe IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 31. APAC IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 32. Row IP&C Market, By Antimicrobial Drugs, 2013-2020 ($Billion)
Table 33. Global IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 34. North America IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 35. Europe IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 36. APAC IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 37. Row IP&C Market, By Types of PPE, 2013-2020 ($Billion)
Table 38. Frequency of Hand Washing & Its Co-Relation In Infection Prevention
Table 39. Global IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 40. North America IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 41. Europe IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 42. APAC IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 43. Row IP&C Market, By Types of Disinfectants, 2013-2020 ($Billion)
Table 44. Global IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 45. North America IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 46. Europe IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 47. APAC IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 48. Row IP&C Market, By Types of Sterilization, 2013-2020 ($Billion)
Table 49. Global IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 50. North America IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 51. Europe IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 52. APAC IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 53. Row IP&C Market, By Types of Autoclave, 2013-2020 ($Million)
Table 54. Global IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 55. North America IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 56. Europe IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 57. APAC IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 58. Row IP&C Market, By Equipments & Accessories End User’s 2013–2020 ($Billion)
Table 59. Global IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 60. North America IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 61. Europe IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 62. APAC IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 63. Row IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 ($Billion)
Table 64. Global IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 65. Global IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 66. North America IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 67. North America IP&C Accessories & Equipment’s Market 2013– 2020 ($Billion)
Table 68. United States IP&C Market Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 69. United States IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 70. Canada IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 71. Canada IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 72. Mexico IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 73. Mexico IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 74. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 75. Others IP&C Accessories & Equipments Market, 2013–2020 ($Billion)
Table 76. Europe IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 77. Europe IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 78. U.K. IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 79. U.K. IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 80. Germany IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 81. Germany IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 82. Italy IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 83. Italy IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 84. Spain IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 85. Spain IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 86. France IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 87. France IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 88. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 89. Others IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 90. APAC IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 91. APAC IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 92. China IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 93. China IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 94. Japan IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 95. Japan IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 96. Korea IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 97. Korea IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 98. India IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 99. India IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 100. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 101. Others IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 102. Row IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 103. Row IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 104. Saudi Arabia IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 105. Saudi Arabia IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 106. South Africa IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 107. South Africa IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 108. Brazil IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 109. Brazil IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 110. Russia IP&C Anti Microbial Drug Market, 2013–2020 ($Billion)
Table 111. Russia IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 112. Others IP&C Anti Microbial Drug Market, 2013–2020 ($Billion))
Table 113. Others IP&C Accessories & Equipment’s Market, 2013– 2020 ($Billion)
Table 114. List of Acquisitions of Global Infection Prevention & Control Market Players
Table 115. List of Product Launches of Global Infection Prevention & Control Market Players
Table 116. List of Collaborations & Strategic Partnerships By Key Players In Global Infection Prevention & Control Market
Table 117. Abbott Revenue, 2013–2020 ($Billion)
Table 118. Alere Inc. Net Revenue - 2011-2013 ($Million)
Table 119. Alere Inc. Net Revenue- By Business Segment, 2010-2013 ($Million)
Table 120. Alere Inc. Net Product Sales and Services Revenue - By Geography Solutions, 2012-2013 ($Million)
Table 121. Ansell Ltd, Total Revenue 2012– 2013 ($Million)
Table 122. Ansell Ltd, Total Revenue, of Medical Segment 2012– 2013 ($Million)
Table 123. Ansell Ltd, Total Revenue, Sales By Region 2012– 2013 ($Million)
Table 124. Astrazeneca Net Revenue: 2011-2013 ($Million)
Table 125. Astrazeneca Net Revenue By Region: 2011-2012 ($Million)
Table 126. C. R. Bard Inc., Net Sales 2011– 2013 ($Million)
Table 127. C. R. Bard Inc., Revenue, By Segment 2013– 2011 ($Million)
Table 128. C.R.Bard Inc., Revenue, By Geography 2013– 2011 ($Million)
Table 129. C.R.Bard Inc., Revenue, R&D 2013– 2011 ($Million)
Table 130. Becton, Dickinson and Company; Net Revenue 2012- 2013 ($Million)
Table 131. Total Revenue; By Division 2012-2013($Million)
Table 132. Total Revenue; By Geography 2012-2013 ($Billion)
Table 133. Cantel Medical Corp. Net Revenue: 2011-2013 ($Million)
Table 134. Cantel Medical Corp. Net Sales By Segments 2011-2013 (%)
Table 135. Covidien, Total Revenue 2013– 2011 ($Million)
Table 136. Covidien, Total Revenue, By Segment 2013– 2011 ($Million)
Table 137. Covidien, Total Revenue, By Region 2013– 2011 ($Million)
Table 138. Covidien, Total Revenue, By R&D 2013– 2011 ($Million)
Table 139. Getinge Group Net Revenue: 2011-2013 ($Million)
Table 140. Getinge Infection Control Ab: Overview 2013 ($Million)
Table 141. Johnson & Johnson: Net Revenue 2011-2013 ($Million)
Table 142. Johnson & Johnson: Sales By Segment 2011-2013 ($Million)
Table 143. Johnson & Johnson: Sales By Region 2011-2013($Million)
Table 144. Johnson & Johnson: Sales of Business Segments In Geographic Areas 2011-2013 ($Million)
Table 145. Kimberly-Clark Net Revenue: 2011-2013 ($Million)
Table 146. Kimberly-Clark: Sales By Segment 2011-2013 ($Million)
Table 147. Kimberly-Clark: Sales By Region 2011-2013 ($Million)
Table 148. Merck & Co., INC Net Sales: 2011-2013 ($Billion)
Table 149. Merck & Co., INC Net Sales of Joint Venture Products: 2011-2013 ($Million)
Table 150. Pfizer Inc. Net Revenue: 2011-2013 ($Million)
Table 151. Pfizer Inc. Total Expenses: 2011-2013 ($Million)
Table 152. Pfizer Inc. Net Revenue By Segment: 2011-2013 ($Million)
Table 153. Pfizer Inc. Net Revenue By Regions: 2011-2013 ($Million)
Table 154. Roche Net Revenue, 2012-2013 ($Million)
Table 155. Roche Net Revenue: By Division, 2012-2013 ($Million)
Table 156. Siemens Ag: Total Revenue, 2012-2013 ($Million)
Table 157. Siemens Ag Revenue: By Divisions, 2011-2013 ($Million)
Table 158. Siemens Ag: Total Revenue By Region 2012-2013($Million)
Table 159. Supermax Corporation Berhad Net Revenue: 2011-2013 ($Million)
Table 160. Tso3 Net Revenue: 2011-2013 ($Million)
Table 161. 3m Net Income and R&D Expenditure of 3m, 2012-2013 ($Billion)


List of Figures:

Figure 1. Infection Prevention & Control Objective
Figure 2. Infection Prevention & Control Market – Classification
Figure 3. Infection Prevention & Control Market – Classification, By Type of Antimicrobial Drugs
Figure 4. Infection Prevention & Control Market, Classification, By Type of Accessories and Equipment
Figure 5. Infection Prevention & Control Market Oclassification, By End-User
Figure 6. Global IP&C Personal Protective Equipment Market, By Geography 2013 (%)
Figure 7. Global IP&C Market, By Geography, 2013 VS 2020 ($Billion)
Figure 8. Global IP&C Market – Market Share Analysis, By Key Players, 2013
Figure 9. IP&C, Patents By Key Players (2012-2014)
Figure 10. IP&C, Total Number of Patents (2010-2014)
Figure 11. IP&C, Total Number of Patents for Hand Sanitizers (2010-2014)
Figure 12. Model Depicting Triple Aim of Healthcare System
Figure 13. Value Chain Analysis of IP&C Market
Figure 14. Average Selling Price Analysis of Personal Protective Equipment Products - By Type, 2013-2020 ($)
Figure 15. Average Selling Price Analysis of Disinfectants, By Type, 2013-2020 ($)
Figure 16. Average Selling Price Analysis of Sterilization Equipment, By Type, 2013-2020 ($)
Figure 17. Average Selling Price Analysis of Autoclaves, By Type, 2013-2020 ($)
Figure 18. Average Selling Price Analysis of Anti-Microbial Drugs, By Type, 2013-2020 ($)
Figure 19. General Life Cycle of a Medical Products/Device
Figure 20. Life Cycle of a Medical Device
Figure 21. Global IP&C Anti Microbial Drugs Market, By Type of Anti-Microbial Infection, 2013 (%)
Figure 22. Global IP&C Accessories & Equipment Market, By Hai, 2013 (%)
Figure 23. Antibiotics Drug Pipeline (1980-2012)
Figure 24. Global IP&C Market, By Antimicrobial Drugs In 2013 (%)
Figure 25. Relationship Between Bacteria, Device & Host Towards Infection
Figure 26. Global IP&C Market, By Types of PPE, 2013 (%)
Figure 27. Global IP&C Market : By Types of Disinfectants In 2013 (%)
Figure 28. Global IP&C Market: By Types of Sterilization In 2013 (%)
Figure 29. Global IP&C Market: By Types of Autoclave In 2013 (%)
Figure 30. Global IP&C Market: By Accessories & Equipment’s End Users In 2013 (%)
Figure 31. Global IP&C Market, By Anti-Microbial Drugs End User’s 2013–2020 In 2013 (%)
Figure 32. Global IP&C Market: By Anti-Microbial Drug (a) and By Accessories & Equipments (B) In 2013 (%)
Figure 33. Infection and Prevention Control Market –By Type of Development (2012-2014)
Figure 34. Global Infection and Prevention Control Market – By Product Launches (2012-2014)
Figure 35. Global Infection and Prevention Control Market- Total Developments 2012 - 2014
Figure 36. Global Infection and Prevention Control Product Launches – By Key Players (2012 - 2014)
Figure 37. Sales By Division In 2013 (%)
Figure 38. Sales By Products In 2013 (%)
Figure 39. Sales By Regions In 2013 (%)
Figure 40. Getinge Group Net Sales: By Division, 2011-2013 (%)
Figure 41. Sales By Therapeutic Area In Pharmaceutical 2013 (%)
Figure 42. Sales By Major Franchise In Medical Devices and Diagnostics 2013 (%)
Figure 43. Sales By Major Franchise In Consumer 2013 (%)
Figure 44. Pharmaceutical Sales By Region In 2013 (%)
Figure 45. Pharmaceutical Sales By Therapeutic Area In 2013 (%)
Please select Licence
Single User Licence:
US $4250
Corporate User Licence:
US $6250
Related Reports
0px;">Scroll